Avalo Therapeutics (NASDAQ:AVTX) Upgraded to "Hold" at Wall Street Zen

robot
Abstract generation in progress

Avalo Therapeutics (NASDAQ:AVTX) was upgraded by Wall Street Zen from a “strong sell” to a “hold” rating, though the consensus among analysts remains a “Moderate Buy” with an average price target of $42.25. Despite beating its last quarterly EPS estimate, the company is unprofitable, with analysts projecting a negative EPS of -19.07 for the current year. Insider trading activity shows a significant sale by Mittie Doyle, reducing their stake, while institutional investors hold a substantial 87.06% of the company’s stock.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin